RecruitingNot Applicable

ARC-IM System to Manage Symptomatic Blood Pressure Instability Secondary to Chronic Spinal Cord Injury

United States60 participantsStarted 2025-10-17

Plain-language summary

Empower BP is a pivotal, interventional, multicenter, prospective, randomized, controlled double-blinded study to evaluate the safety and effectiveness of the ARC-IM System in managing symptomatic blood pressure instability in individuals with chronic SCI (\>1 year after SCI). The primary effectiveness outcome will be evaluated through subject-reported ADFSCI and seated blood pressure assessments at 3 months post-implant. Following a baseline screening period and the surgical implantation of the ARC-IM System, subjects will be randomized with a 2:1 ratio into an active or control arm for 3 months. All the subjects will undergo therapy activation sessions (into either Group 1: active intervention, or Group 2: intervention aimed to mimic the active intervention without the active component) within 21 days of the surgical implant and will then commence independent at-home use of ARC-IM Therapy. At the 3 Month timepoint, after all assessments are conducted, all subjects will transition to the open-label period in order to receive the active version of the ARC-IM System in an open-label fashion. All subjects will undergo therapy programming sessions following Month 3.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18 years or above, and no older than 75 years at the time of enrollment.
✓. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria.
✓. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication.
✓. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score
✓. A Spinal cord injury at the neurologic level between C2 and T6 inclusive.
✓. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D.
✓. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry.
✓. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation

Exclusion criteria

What they're measuring

Proportion of subjects achieving a change in the hypotension domain of the ADFSCI short-form questionnaire

Timeframe: 3-months post-implant

Proportion of subjects achieving elevation in SBP during seated BP test

Timeframe: 3-months post-implant

Incidence of serious adverse device effects

Timeframe: 6-months post-implant

Trial details

NCT IDNCT07147296

SponsorONWARD Medical, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-11

View on ClinicalTrials.gov More Spinal Cord Injuries trials

Plain-language summary

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Aged 18 years or above, and no older than 75 years at the time of enrollment.
✓. Clinical evidence of Orthostatic Hypotension (blood pressure drop of 20mmHg systolic or 10mmHg diastolic) measured during Head Up Tilt Table assessment (HUTT, within 10 minutes) with current standard of care if any. 2 out of 3 tests must meet OH criteria.
✓. Clinical evidence of sustained hypotension (average systolic Blood pressure ≤ 110 mmHg) when measured each minute for 10 minutes while seated and in the absence of supportive compressive garments and medication.
✓. Evidence of symptomatic hypotension as determined by a non-zero OHSA total score
✓. A Spinal cord injury at the neurologic level between C2 and T6 inclusive.
✓. American Spinal Injury Association (ASIA) Impairment Scale (AIS) classification A, B, C, or D.
✓. Traumatic (non-progressive) chronic spinal cord injury with minimum 12 months post-injury prior to study entry.
✓. Average A-P diameter of the sponal canal ≥ 13 mm, measured on MRI at the disc space at level(s) planned for implantation

Exclusion criteria

What they're measuring

Proportion of subjects achieving a change in the hypotension domain of the ADFSCI short-form questionnaire

Timeframe: 3-months post-implant

Proportion of subjects achieving elevation in SBP during seated BP test

Timeframe: 3-months post-implant

Incidence of serious adverse device effects

Timeframe: 6-months post-implant